C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: results of an Italian/Swiss multicenter survey
Andrea Mancuso,S. Sacchetta,P. Saletti,C. Tronconi,L. Milesi,Marina Chiara Garassino,Olga Martelli,Roberto Labianca,F. Cavalli,Cora N. Sternberg +9 more
TL;DR: The results of this study indicate that ERCC1 may predict survival in pancreatic cancer patients treated by platinum and fluoropyrimidine as second-line chemotherapy.
Journal ArticleDOI
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
Cora N. Sternberg,Daniel Castellano,Johann S. de Bono,Karim Fizazi,Bertrand F. Tombal,Christian Wülfing,Gero Kramer,Jean-Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Asgerdur Sverrisdottir,Christine Theodore,Susan Feyerabend,Carole Helissey,Elizabeth M. Poole,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Ronald de Wit +19 more
TL;DR: Radiographic PFS, PFS and OS were significantly improved with CBZ vs. androgen-signaling-targeted agents (ARTA; ABI or ENZ) in pts with mCRPC...
Journal ArticleDOI
802TiPPROSPER: A PHASE 3 STUDY OF ENZALUTAMIDE IN NON-METASTATIC (M0) CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
Cora N. Sternberg,Karim Fizazi,Fred Saad,N.D. Shore,Axel Heidenreich,M. Hirmand,Frank Perabo,Z. Khondker,Katharina Modelska,Maha Hussain +9 more
TL;DR: PROSPER is a randomized, double-blind, placebo-controlled, Phase 3 study involving more than 200 sites in the United States, Canada, Europe, South America and the Asia Pacific region and involving patients with a PSA >8 ng/mL or PSA doubling time of more than 10 months.
Journal ArticleDOI
433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC)
Stéphane Oudard,Nadine Benhamouda,B. Escudier,P Ravel,D Kothari,Faisal Mehmud,Emeline Levionnois,Emmanuel Sevin,Sylvie Negrier,Philippe Barthélémy,Jean-François Berdah,Alain Ravaud,Cora N. Sternberg,Petri Bono,C. Porta,U. De Giorgi,Omi Parikh,Robert E. Hawkins,M Highley,Eric Tartour,T Decker,J Wilkie +21 more
Journal ArticleDOI
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
Daniel P. Petrylak,Scott T. Tagawa,Rohit Jain,Manoj Bupathi,Arjun Vasant Balar,Arash Rezazadeh,Saby George,Phillip L. Palmbos,Luke Nordquist,Nancy B. Davis,Chethan Ramamurthy,Cora N. Sternberg,Yohann Loriot,Neeraj Agarwal,Chandler H. Park,Julia Tonelli,Morganna Vance,Hua Feng Zhou,Petros Grivas +18 more
TL;DR: Tagawa et al. as discussed by the authors reported the results of the phase 2 TROPHY-U-01 Cohort 2 study and showed that SG monotherapy demonstrated a high response rate with an overall manageable safety profile in PT-ineligible pts with locally advanced or mUC who progressed after CPI therapy.